Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial
Authors:
- 26 July 2024
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 24 (11) , 1245-1253
Abstract
No abstract availableKeywords
Funding Information
- Coalition for Epidemic Preparedness Innovations
- Horizon 2020 Framework Programme
- Deutsche Forschungsgemeinschaft (398066876/GRK 2485/2)
This publication has 29 references indexed in Scilit:
- Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in miceApplied Microbiology and Biotechnology, 2024
- Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trialThe Lancet Infectious Diseases, 2023
- Aedes albopictus invasion across Africa: the time is now for cross-country collaboration and controlThe Lancet Global Health, 2023
- Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn GlycoproteiniScience, 2020
- Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancyVaccine, 2017
- Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional studyThe Lancet Global Health, 2016
- Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humansVaccine, 2016
- Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolatesVaccine, 2016
- Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccinationVaccine, 2015
- Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experienceVaccine, 1999